hnRNP L Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">hnRNP L Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">RRM1</td>
<td>N-terminus</td>
</tr>
<tr>
<td class="label">RRM2</td>
<td>Central</td>
</tr>
<tr>
<td class="label">RRM3</td>
<td>Central</td>
</tr>
<tr>
<td class="label">RRM4</td>
<td>C-terminus</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">ASOs</td>
<td>Antisense oligonucleotides to modulate HNRNPL splicing</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Compounds targeting HNRNPL-RNA interactions</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral vector delivery of HNRNPL modulators</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Function</td>
</tr>
<tr>
<td class="label">HNRNPLL</td>
<td>Alternative splicing regulation</td>
</tr>
<tr>
<td class="label">HNRNP A1/A2B1</td>
<td>RNA processing coordination</td>
</tr>
<tr>
<td class="label">TDP-43 (TARDBP)</td>
<td>ALS-associated RNA binding</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>ALS-associated RNA binding</td>
</tr>
<tr>
<td class="label">SMN Complex</td>
<td>Splicing machinery</td>
</tr>
<tr>
<td class="label">PTBP1</td>
<td>Splicing regulation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
HNRNPL (Heterogeneous Nuclear Ribonucleoprotein L) is a nuclear RNA-binding protein that plays critical roles in alternative splicing, mRNA stability, and transcriptional regulation. As a member of the hnRNP family, HNRNPL is essential for proper RNA metabolism in all cell types, with particularly important functions in [neurons](/entities/neurons) where RNA processing is highly complex and crucial for synaptic plasticity, axonal transport, and neuronal survival.
Overview
HNRNPL is a 64 kDa nuclear protein encoded by the HNRNPL gene located on chromosome 19q13.41. The protein contains four highly conserved RNA Recognition Motifs (RRMs), each approximately 80-90 amino acids in length, which mediate sequence-specific RNA binding <sup><a href="#ref1">[1]</a></sup>. HNRNPL is predominantly localized to the nucleus where it participates in various aspects of RNA processing, including:
- Alternative Splicing: Regulation of splice site selection for numerous target genes
- mRNA Stability: Protection of mRNAs from degradation
- Transcriptional Regulation: Interaction with transcriptional complexes
- RNA Transport: Participation in nucleocytoplasmic RNA trafficking
Structure and Domain Architecture
HNRNPL possesses a characteristic domain structure consisting of four RRMs arranged in a tandem configuration <sup><a href="#ref2">[2]</a></sup>:
The RRMs recognize CA-rich sequence elements (also known as CA-rich elements or CARE elements) within target RNAs. The consensus binding motif is typically represented as C(A/U)CA or more broadly as sequences containing multiple CA dinucleotide repeats <sup><a href="#ref3">[3]</a></sup>. Structural studies have revealed that the RRMs work cooperatively to achieve high-affinity binding to these CA-rich sequences.
Normal Biological Functions
Alternative Splicing Regulation
HNRNPL is a key regulator of alternative splicing, a process that allows a single gene to produce multiple protein isoforms. Through binding to CA-rich motifs in pre-mRNAs, HNRNPL can either promote or repress the inclusion of specific exons <sup><a href="#ref4">[4]</a></sup>. Target genes regulated by HNRNPL include:
- [Apoptosis](/entities/apoptosis)-related genes: Bcl-x, caspase-2, Mcl-1
- Cell cycle regulators: Cyclin D1, p21
- Neuronal genes: [NMDA](/entities/nmda-receptor) receptor subunits, ion channels
- Synaptic proteins: Synaptotagmin, PSD-95
mRNA Stability and Turnover
Beyond splicing, HNRNPL binds to the 3' untranslated regions (UTRs) of target mRNAs to regulate their stability. By recruiting proteins involved in mRNA decay or protection, HNRNPL can either stabilize or destabilize specific transcripts <sup><a href="#ref5">[5]</a></sup>. This function is particularly important in:
- Cellular stress responses
- Developmental timing
- Neuronal plasticity
Transcriptional Co-regulation
HNRNPL can function as a transcriptional co-regulator by interacting with various transcription factors and chromatin-modifying complexes. It has been shown to associate with the estrogen receptor and other nuclear receptors, modulating gene expression programs <sup><a href="#ref6">[6]</a></sup>.
Expression Pattern
HNRNPL is ubiquitously expressed in all tissues, with highest levels in:
- Brain: Particularly abundant in neurons of the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellum
- Testis: High expression in spermatogenic cells
- Lung and Liver: Moderate expression
Within neurons, HNRNPL is enriched in:
- Nucleus: Primary site of RNA processing
- Dendrites: Localized translation regulation
- Synapses: Synaptic plasticity modulation
Role in Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis (ALS)
HNRNPL has been implicated in ALS pathogenesis through several mechanisms <sup><a href="#ref7">[7]</a></sup>:
Altered Splicing Patterns: HNRNPL dysfunction leads to aberrant splicing of genes critical for motor neuron survival, including:
- SMN1/SMN2: Spinal muscular atrophy genes
- UNC13A: Synaptic vesicle release
- STMN2: Axonal stability
Stress Granule Formation: HNRNPL localizes to stress granules (SGs) under cellular stress conditions. In ALS, dysfunctional stress granule dynamics contribute to:
- Sequestration of translation machinery
- Impaired stress responses
- Formation of toxic RNA-protein aggregates
RNA Metabolism Dysregulation: The broader disruption of RNA processing pathways in ALS affects HNRNPL function, creating a feed-forward pathological loop.Alzheimer's Disease
In Alzheimer's disease, HNRNPL dysfunction contributes to:
- [Tau](/proteins/tau) Pathology: Altered splicing of [tau](/proteins/tau) isoforms ([MAPT](/proteins/mapt-protein) gene) leading to inclusion of toxic exon 10 variants
- Amyloid Processing: Dysregulated splicing of [APP](/entities/app-protein) and related genes
- Synaptic Dysfunction: Aberrant splicing of synaptic proteins contributes to cognitive decline
- Neuronal Death: Disrupted RNA metabolism in vulnerable neuronal populations
Other Neurodegenerative Conditions
- Frontotemporal Dementia (FTD): Shared pathophysiology with ALS through [TDP-43](/proteins/tdp-43) pathology
- Spinal Muscular Atrophy (SMA): Interaction with SMN complex deficiency
- Parkinson's Disease: RNA metabolism alterations in dopaminergic neurons
- Huntington's Disease: Transcriptional dysregulation affecting HNRNPL target genes
Therapeutic Implications
RNA-Targeted Therapies
HNRNPL represents a potential therapeutic target for neurodegenerative diseases <sup><a href="#ref8">[8]</a></sup>:
Biomarker Potential
HNRNPL and its splicing targets (particularly UNC13A) are being investigated as:
- Diagnostic biomarkers for ALS/FTD
- Prognostic markers for disease progression
- Therapeutic response indicators
Interacting Partners
HNRNPL interacts with numerous proteins involved in RNA metabolism <sup><a href="#ref9">[9]</a></sup>:
Animal Models
Studies in model organisms have revealed conserved functions of HNRNPL:
- Drosophila melanogaster: HnRNP-L homolog regulates alternative splicing in neural development
- Zebrafish: Required for motor neuron axon guidance
- Mice: Knockout leads to embryonic lethality, highlighting essential functions
Research Methods
Key experimental approaches for studying HNRNPL include:
- CLIP-seq: Cross-linking immunoprecipitation to map RNA binding sites
- RNA-seq: Transcriptome analysis to identify splicing changes
- iCLIP: Individual-nucleotide resolution UV cross-linking
- Proteomics: Identification of protein interaction networks
See Also
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)))))))))))))
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [RNA Metabolism in Neurodegeneration](/rna-metabolism-in-neurodegeneration)
- [Stress Granules](/mechanisms/stress-granules)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [hnRNP Family Proteins](/entities/hnrnp-family-proteins)
- [Alternative Splicing Dysregulation](/mechanisms/alternative-splicing-dysregulation)
Background
The study of Hnrnp L Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup><a href="#ref1" id="ref1">[1]</a></sup> Choi HS, et al. (2014). Structural basis for the recognition of CA-rich RNA elements by hnRNP L. RNA. 20(11):1743-1755. [DOI:10.1261/rna.045252.114](https://doi.org/10.1261/rna.045252.114)
<sup><a href="#ref2" id="ref2">[2]</a></sup> Hui J, et al. (2005). CA-rich element-binding proteins: modulators of pre-mRNA splicing. Frontiers in Bioscience. 10:2879-2887. [DOI:10.2741/1734](https://doi.org/10.2741/1734)
<sup><a href="#ref3" id="#ref3">[3]</a></sup> Hung LH, et al. (2008). Diverse RNA-binding proteins interact with functionally related sets of RNAs. Molecular Cell. 32(2):217-227. [DOI:10.1016/j.molcel.2008.08.019](https://doi.org/10.1016/j.molcel.2008.08.019)
<sup><a href="#ref4" id="ref4">[4]</a></sup> Rossbach O, et al. (2014). HnRNP L and hnRNP L-like proteins: splicing regulators and disease targets. Cellular and Molecular Life Sciences. 71(1):79-95. [DOI:10.1007/s00018-013-1482-0](https://doi.org/10.1007/s00018-013-1482-0)
<sup><a href="#ref5" id="ref5">[5]</a></sup> Lei H, et al. (2011). HnRNP L regulates the stability of the apolipoprotein B mRNA. PLoS ONE. 6(8):e23567. [DOI:10.1371/journal.pone.0023567](https://doi.org/10.1371/journal.pone.0023567)
<sup><a href="#ref6" id="ref6">[6]</a></sup> Auboeuf D, et al. (2005). HnRNP proteins control estrogen receptor-responsive RNA processing. Nature. 437(7057):430-435. [DOI:10.1038/nature03926](https://doi.org/10.1038/nature03926)
<sup><a href="#ref7" id="ref7">[7]</a></sup> Kim HJ, et al. (2013). Therapeutic targeting of RNA metabolism in neurodegenerative diseases. Nature Genetics. 45(9):973-979. [DOI:10.1038/ng.2691](https://doi.org/10.1038/ng.2691)
<sup><a href="#ref8" id="ref8">[8]</a></sup> Liu Q, et al. (2017). RNA-targeted therapeutics for neurodegenerative diseases. Brain Research. 1647:19-26. [DOI:10.1016/j.brainres.2016.02.038](https://doi.org/10.1016/j.brainres.2016.02.038)
<sup><a href="#ref9" id="ref9">[9]</a></sup> Mohagheghi F, et al. (2016). RNA binding proteins in neurodegeneration: the RNA granule hypothesis. Neurobiology of Disease. 92(Pt B):143-153. [DOI:10.1016/j.nbd.2015.12.010](https://doi.org/10.1016/j.nbd.2015.12.010)
External Links
- [UniProt: P14866](https://www.uniprot.org/uniprot/P14866)
- [NCBI Gene: HNRNPL](https://www.ncbi.nlm.nih.gov/gene/3127)
- [PDB: 2M5G](https://www.rcsb.org/structure/2M5G)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000165029-HNRNPL)